Read the full press release here: http://biz.yahoo.com/prnews/110531/da11393.html?.v=1
About Lexicon Pharmaceuticals, Inc.:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases in the areas of cardiology, gastroenterology, immunology, metabolism, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology. Lexicon Pharmaceuticals, Inc. was formerly known as Lexicon Genetics Inc. and changed its name on April 26, 2007. The company was founded in 1995 and is headquartered in The Woodlands, Texas.
Subscribe free at http://pennystockrumors.net
This is not an offer to buy or sell securities. Information or opinions are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. Neither PennyStockRumors.net nor any of its employees, affiliates, subsidiaries or family members are registered investment advisors or registered stock brokers and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site. Do not buy any stock PennyStockRumors.net mentions. We are not liable for any investment decisions by our readers. By way of visit to this webpage, you agree to indemnify and hold harmless PennyStockRumors, its employees and owners against any and all actions, claims, damages, obligations, losses, proceedings, expenses and liabilities.
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/press_release_distribution_lists.php.